• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嵌合抗原受体的铰链和跨膜结构域调节受体表达和信号转导阈值。

Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold.

机构信息

Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.

出版信息

Cells. 2020 May 9;9(5):1182. doi: 10.3390/cells9051182.

DOI:10.3390/cells9051182
PMID:32397414
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7291079/
Abstract

Chimeric antigen receptor (CAR)-T cells have demonstrated significant clinical potential; however, their strong antitumor activity may cause severe adverse effects. To ensure efficacy and safe CAR-T cell therapy, it is important to understand CAR's structure-activity relationship. To clarify the role of hinge and transmembrane domains in CAR and CAR-T cell function, we generated different chimeras and analyzed their expression levels and antigen-specific activity on CAR-T cells. First, we created a basic CAR with hinge, transmembrane, and signal transduction domains derived from CD3ζ, then we generated six CAR variants whose hinge or hinge/transmembrane domains originated from CD4, CD8α, and CD28. CAR expression level and stability on the T cell were greatly affected by transmembrane rather than hinge domain. Antigen-specific functions of most CAR-T cells depended on their CAR expression levels. However, CARs with a CD8α- or CD28-derived hinge domain showed significant differences in CAR-T cell function, despite their equal expression levels. These results suggest that CAR signaling intensity into T cells was affected not only by CAR expression level, but also by the hinge domain. Our discoveries indicate that the hinge domain regulates the CAR signaling threshold and the transmembrane domain regulates the amount of CAR signaling via control of CAR expression level.

摘要

嵌合抗原受体 (CAR)-T 细胞已显示出显著的临床潜力;然而,其强大的抗肿瘤活性可能会引起严重的不良反应。为了确保 CAR-T 细胞治疗的疗效和安全性,了解 CAR 的结构-活性关系非常重要。为了阐明铰链和跨膜结构域在 CAR 和 CAR-T 细胞功能中的作用,我们构建了不同的嵌合体,并分析了它们在 CAR-T 细胞上的表达水平和抗原特异性活性。首先,我们构建了一个基本的 CAR,其铰链、跨膜和信号转导结构域来源于 CD3ζ,然后我们构建了六个 CAR 变体,其铰链或铰链/跨膜结构域来源于 CD4、CD8α 和 CD28。跨膜结构域而非铰链结构域极大地影响了 T 细胞上 CAR 的表达水平和稳定性。大多数 CAR-T 细胞的抗原特异性功能取决于其 CAR 的表达水平。然而,源自 CD8α 或 CD28 的铰链域的 CAR 尽管表达水平相等,但在 CAR-T 细胞功能上表现出显著差异。这些结果表明,CAR 信号转导进入 T 细胞不仅受到 CAR 表达水平的影响,还受到铰链结构域的影响。我们的发现表明,铰链结构域调节 CAR 信号的阈值,而跨膜结构域通过控制 CAR 的表达水平来调节 CAR 信号的量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/d63487e5ef29/cells-09-01182-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/f635b0d391de/cells-09-01182-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/c83beab46bd2/cells-09-01182-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/e9d3f52677c2/cells-09-01182-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/873c7c0c3caa/cells-09-01182-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/d63487e5ef29/cells-09-01182-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/f635b0d391de/cells-09-01182-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/c83beab46bd2/cells-09-01182-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/e9d3f52677c2/cells-09-01182-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/873c7c0c3caa/cells-09-01182-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d010/7291079/d63487e5ef29/cells-09-01182-g005a.jpg

相似文献

1
Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold.嵌合抗原受体的铰链和跨膜结构域调节受体表达和信号转导阈值。
Cells. 2020 May 9;9(5):1182. doi: 10.3390/cells9051182.
2
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.新型含人源可变区的抗 CD19 嵌合抗原受体的功能受铰链和跨膜结构域影响。
Mol Ther. 2017 Nov 1;25(11):2452-2465. doi: 10.1016/j.ymthe.2017.07.013. Epub 2017 Jul 27.
3
Modification of Hinge/Transmembrane and Signal Transduction Domains Improves the Expression and Signaling Threshold of GXMR-CAR Specific to spp.铰链/跨膜和信号转导结构域的修饰提高了 GXMR-CAR 对 spp. 的表达和信号转导阈值的特异性。
Cells. 2022 Oct 26;11(21):3386. doi: 10.3390/cells11213386.
4
Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals.第二代嵌合抗原受体信号转导结构域调控 CAR 信号输入效率
Int J Mol Sci. 2021 Mar 1;22(5):2476. doi: 10.3390/ijms22052476.
5
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.嵌合抗原受体信号的磷酸化蛋白质组学分析揭示了影响细胞功能的动力学和定量差异。
Sci Signal. 2018 Aug 21;11(544):eaat6753. doi: 10.1126/scisignal.aat6753.
6
Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells.抗原非依赖激活对于 GUCY2C 靶向 CAR-T 细胞的持久抗肿瘤效果至关重要。
J Immunother Cancer. 2024 Oct 4;12(10):e009960. doi: 10.1136/jitc-2024-009960.
7
Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.新型抗 CD30 嵌合抗原受体的设计与评估,其具有人源抗原识别结构域。
Hum Gene Ther. 2021 Jul;32(13-14):730-743. doi: 10.1089/hum.2020.215. Epub 2021 Feb 22.
8
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.引入铰链区可改善嵌合抗原受体T细胞的扩增。
J Hematol Oncol. 2017 Mar 13;10(1):68. doi: 10.1186/s13045-017-0437-8.
9
CD28 hinge used in chimeric antigen receptor (CAR) T-cells exhibits local structure and conformational exchange amidst global disorder.嵌合抗原受体 (CAR) T 细胞中的 CD28 铰链在整体无序中表现出局部结构和构象交换。
Commun Biol. 2024 Aug 31;7(1):1072. doi: 10.1038/s42003-024-06770-w.
10
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.CD28-跨膜结构域介导嵌合抗原受体与 CD28 的异二聚化。
Front Immunol. 2021 Mar 23;12:639818. doi: 10.3389/fimmu.2021.639818. eCollection 2021.

引用本文的文献

1
Tracing the development of CAR-T cell design: from concept to next-generation platforms.追溯嵌合抗原受体T细胞(CAR-T)设计的发展:从概念到下一代平台。
Front Immunol. 2025 Jul 17;16:1615212. doi: 10.3389/fimmu.2025.1615212. eCollection 2025.
2
CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions.嵌合抗原受体T细胞免疫疗法作为癌症根除的新希望:现状、挑战与未来方向
Med Oncol. 2025 Aug 6;42(9):410. doi: 10.1007/s12032-025-02957-1.
3
CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy.

本文引用的文献

1
Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.嵌合抗原受体中 scFv 结构对受体表达效率和抗原识别特性的影响。
Biochem Biophys Res Commun. 2020 Jun 25;527(2):350-357. doi: 10.1016/j.bbrc.2020.03.071. Epub 2020 Mar 23.
2
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment.推进实体瘤的嵌合抗原受体T细胞疗法:从淋巴瘤治疗中汲取的经验教训。
Cancers (Basel). 2020 Jan 3;12(1):125. doi: 10.3390/cancers12010125.
3
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.
嵌合抗原受体T细胞与自身免疫性神经疾病:治疗的新曙光
Front Immunol. 2025 Jul 18;16:1604174. doi: 10.3389/fimmu.2025.1604174. eCollection 2025.
4
Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases.基于嵌合抗原受体的自身免疫性疾病免疫治疗研究进展
Hum Vaccin Immunother. 2025 Dec;21(1):2538350. doi: 10.1080/21645515.2025.2538350. Epub 2025 Aug 1.
5
Targets for CAR Therapy in Multiple Myeloma.多发性骨髓瘤中CAR疗法的靶点
Int J Mol Sci. 2025 Jun 24;26(13):6051. doi: 10.3390/ijms26136051.
6
CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation.CD2增强通过免疫突触重塑和减轻T细胞耗竭来提高CAR-T细胞疗效。
Cell Mol Immunol. 2025 Jul 4. doi: 10.1038/s41423-025-01314-6.
7
A universal chimeric antigen receptor (CAR)-fragment antibody binder (FAB) split system for cancer immunotherapy.一种用于癌症免疫治疗的通用嵌合抗原受体(CAR)-片段抗体结合物(FAB)拆分系统。
Sci Adv. 2025 Jul 4;11(27):eadv4937. doi: 10.1126/sciadv.adv4937.
8
Cell-Based Therapies for Solid Tumors: Challenges and Advances.实体瘤的细胞疗法:挑战与进展
Int J Mol Sci. 2025 Jun 9;26(12):5524. doi: 10.3390/ijms26125524.
9
Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond.从天然受体到合成受体的转变:拓展T细胞工程及其他领域
Cell Mol Immunol. 2025 Jun 6. doi: 10.1038/s41423-025-01304-8.
10
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.头颈部鳞状细胞癌的嵌合抗原受体T细胞(CAR-T)疗法的进展与挑战
Biomark Res. 2025 May 1;13(1):69. doi: 10.1186/s40364-025-00783-1.
4-1BB或CD28共刺激的靶向CD19的CAR-T细胞治疗B细胞非霍奇金淋巴瘤的平行比较
Mol Ther Oncolytics. 2019 Aug 28;15:60-68. doi: 10.1016/j.omto.2019.08.002. eCollection 2019 Dec 20.
4
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.嵌合抗原受体在癌症治疗设计中的局限性。
Cells. 2019 May 17;8(5):472. doi: 10.3390/cells8050472.
5
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.联合CD28和4-1BB共刺激增强亲和力优化的嵌合抗原受体工程化T细胞。
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.
6
Engineering and Design of Chimeric Antigen Receptors.嵌合抗原受体的工程设计
Mol Ther Methods Clin Dev. 2018 Dec 31;12:145-156. doi: 10.1016/j.omtm.2018.12.009. eCollection 2019 Mar 15.
7
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
8
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.嵌合抗原受体 T 细胞(CAR-T)免疫疗法治疗实体瘤:经验教训与前进策略。
J Hematol Oncol. 2018 Feb 13;11(1):22. doi: 10.1186/s13045-018-0568-6.
9
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
10
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.通过 ICOS 和 4-1BB 共刺激增强 CAR T 细胞的持久性。
JCI Insight. 2018 Jan 11;3(1). doi: 10.1172/jci.insight.96976.